Novo Nordisk and Anthropic Announce Collaboration to Test Claude Science in Research and Development Workflows
Novo Nordisk and Anthropic announced on Wednesday, September 16, 2026 a collaboration under which Novo Nordisk will test Anthropic's Claude Science in specific research and development workflows and use Anthropic's frontier models for biological reasoning, drug discovery, and AI-driven software development. Financial terms were not disclosed. Novo Nordisk CEO Mike Doustdar said AI can help the company increase R&D productivity and "compress the path from research to marketed product." Anthropic co-founder and CEO Dario Amodei said giving researchers access to frontier models can shorten research timelines.